IGF-1 LR3: What It Is and Its U.S. Regulatory Status

What is IGF-1 LR3?

IGF-1 LR3 (Long R3 IGF-1) is a modified version of insulin-like growth factor 1 (IGF-1), a hormone made mainly in the liver in response to growth hormone. The analog has one amino acid changed, at position 3, and a short extension added to the start of the chain.

These changes reduce how strongly the molecule binds to the proteins that normally hold IGF-1 in the blood, which gives it a longer-lasting effect in laboratory settings. IGF-1 LR3 is widely used as an ingredient in cell culture for research and manufacturing.

U.S. regulatory status

Current status: Not FDA-approved.

In practical terms, IGF-1 LR3 has not gone through the FDA review that a drug must pass before it can be marketed for use in people. There is no FDA-approved product that contains it.

It should not be confused with mecasermin (Increlex), a recombinant form of natural IGF-1 that is FDA-approved for a rare growth disorder. IGF-1 and its analogs are also prohibited in competitive sport under the World Anti-Doping Code.

Why Peptide Labs does not sell IGF-1 LR3

Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply, prepare or distribute IGF-1 LR3 in any form, and nothing on this page should be read as an offer.

If you have questions about IGF-1 LR3 or a related health concern, talk to a licensed healthcare provider who knows your medical history.

Related reading

See the full list of compound profiles in the Peptide Guide.